Replimune

Oncolytic immunotherapy

Also 4 additional trials Clin1/Clin2/Clin3 multiple cancers, organ transplant; RP2 4 trials Clin1/Clin2 multiple cancers; RP3 Clin1 solid tumors

Replimune is developing novel oncolytic immunotherapies to revolutionize cancer treatment. Cancers thrive by suppressing the body’s natural immune response against them. By designing oncolytic immunotherapies that kill the tumor locally, Replimune is altering the tumor microenvironment to ignite a powerful patient-specific immune response. Oncolytic immunotherapies involve the use of viruses that selectively kill human cancer cells. Replimune has developed a robust pipeline of therapies that uses their engineered HSV-1 virus strain and immune activating transgenes to maximize immune cell activation.